# Pharmacokinetic and Safety Study of Pixantrone in Patients With Metastatic Cancer and Hepatic Impairment

> **NCT01632436** · PHASE1 · WITHDRAWN · sponsor: **CTI BioPharma**

## Conditions studied

- Metastatic Cancer

## Interventions

- **DRUG:** Pixantrone

## Key facts

- **NCT ID:** NCT01632436
- **Lead sponsor:** CTI BioPharma
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2012-05
- **Primary completion:** 2017-08
- **Final completion:** 2018-02
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** No eligible patients enrolled
- **Last updated:** 2023-10-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01632436

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01632436, "Pharmacokinetic and Safety Study of Pixantrone in Patients With Metastatic Cancer and Hepatic Impairment". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT01632436. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*